PremiumThe FlySyndax price target lowered to $42 from $45 at Citi Promising Outlook for Syndax Pharmaceuticals: Buy Rating Supported by Revuforj Launch and Strategic Positioning Syndax Pharmaceuticals: Navigating Revenue Growth Amidst Regulatory and Market Challenges PremiumThe FlySyndax reports Q4 EPS ($1.10) vs ($1.00) last year Is SNDX a Buy, Before Earnings? Scotiabank would buy Kura on weakness despite KOMET-001 uncertainty PremiumThe FlyKura Oncology price target lowered to $18 from $22 at Scotiabank Syndax price target raised to $38 from $33 at JPMorgan Syndax price target raised to $45 from $37 at Citi 
